Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311752815> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4311752815 abstract "Abstract Background Invasive fusariosis (IF) is an uncommon opportunistic mold infection primarily affecting patients (pts) with leukemia and allogeneic hematopoietic cell transplant (HSCT). Historically, IF had poor outcome when there is lack of recovery from immunosuppression. However, IF incidence and outcome in the in the era of new mold-active triazoles and leukemia regimens that incorporate molecularly targeted drugs is unknown. Methods We retrospectively studied the incidence, risk factors, clinical features, and outcome of microbiologically documented IF (revised EORTC/MSG criteria) in pts with leukemia at MD Anderson Cancer Center in the last 12 years (June 2009-October 2021). The independent risk factors for 42-day (d) mortality from IF diagnosis were assessed by a binary multivariable logistic regression model. Annual incidence density (1998-2021) was estimated using Poisson regression analysis. Results Among 140 IF pts (114 proven, 26 probable), 100 (71%) had pneumonia, 88 (63%) disseminated infection, and 32 (23%) sinusitis, with no apparent changes in relative frequency over the years. 124 pts (89%) had neutropenia (ANC < 500) at IF diagnosis, 118 (84%) had relapsed/refractory (R/R) leukemia, and 43 (31%) had prior HSCT. 19% (18/97 pts) of IF pts had positive serum galactomannan and 55% had coinfections. In the last 5 years of the study, 45/58 IF cases (78%) were breakthrough infections to mold active triazoles (12 voriconazole, 25 posaconazole, 8 isavuconazole). 74 (53%) out of the 140 IF pts died by d42. Only 6 pts (9%) had neutrophil recovery at time of death compared to 47 (64%) who survived until day 42 (P < 0.001). Neutrophil recovery (aOR 0.04, 95% CI 0.01-0.14), SOFA score (aOR 1.91 per point, 95% CI 1.47-2.50), and pneumonia (aOR 3.28, 95% CI 1.11-9.70) were independent predictors of 42-d mortality. Since 1998, the incidence density of IF continuously increased (P = 0.006) at an annual ratio of 1.05 (95% CI 1.02-1.07, Figure 1). Figure 1Incidence density of invasive fusariosis (per 100,000 patient-days) in leukemia patients between 1998 and 2021 Conclusion Over the past 23 years, IF incidence has been increasing. IF is predominantly seen in pts with R/R acute leukemia and increasingly seen as a breakthrough infection to mold-active triazoles. Even in contemporary pt cohorts, IF has high mortality in the setting of persistent myelosuppression. Disclosures Russell E. Lewis, PharmD, Air: Advisor/Consultant|Cidara: Advisor/Consultant|F2G: Advisor/Consultant|Gilead: Advisor/Consultant|Merck & Co, Inc: Grant/Research Support|Synexis: Advisor/Consultant Dimiitrios P. Kontoyiannis, MD, ScD, PhD (hon), AbbVie: Advisor/Consultant|Astellas Pharma: Advisor/Consultant|Astellas Pharma: Grant/Research Support|Astellas Pharma: Honoraria|Cidara Therapeutics: Advisor/Consultant|Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Gilead Sciences: Honoraria|Merck: Advisor/Consultant." @default.
- W4311752815 created "2022-12-28" @default.
- W4311752815 creator A5004661487 @default.
- W4311752815 creator A5024822266 @default.
- W4311752815 creator A5029750735 @default.
- W4311752815 creator A5031479448 @default.
- W4311752815 creator A5040800962 @default.
- W4311752815 creator A5054028928 @default.
- W4311752815 creator A5066067579 @default.
- W4311752815 date "2022-12-01" @default.
- W4311752815 modified "2023-09-26" @default.
- W4311752815 title "2114. Invasive fusariosis in the era of mold active azoles and molecular targeted chemotherapy: Increasing incidence and lack of improved outcomes" @default.
- W4311752815 doi "https://doi.org/10.1093/ofid/ofac492.1735" @default.
- W4311752815 hasPublicationYear "2022" @default.
- W4311752815 type Work @default.
- W4311752815 citedByCount "0" @default.
- W4311752815 crossrefType "journal-article" @default.
- W4311752815 hasAuthorship W4311752815A5004661487 @default.
- W4311752815 hasAuthorship W4311752815A5024822266 @default.
- W4311752815 hasAuthorship W4311752815A5029750735 @default.
- W4311752815 hasAuthorship W4311752815A5031479448 @default.
- W4311752815 hasAuthorship W4311752815A5040800962 @default.
- W4311752815 hasAuthorship W4311752815A5054028928 @default.
- W4311752815 hasAuthorship W4311752815A5066067579 @default.
- W4311752815 hasBestOaLocation W43117528151 @default.
- W4311752815 hasConcept C120665830 @default.
- W4311752815 hasConcept C121332964 @default.
- W4311752815 hasConcept C121608353 @default.
- W4311752815 hasConcept C126322002 @default.
- W4311752815 hasConcept C141071460 @default.
- W4311752815 hasConcept C16005928 @default.
- W4311752815 hasConcept C2776694085 @default.
- W4311752815 hasConcept C2777063308 @default.
- W4311752815 hasConcept C2777408962 @default.
- W4311752815 hasConcept C2778461978 @default.
- W4311752815 hasConcept C2778566413 @default.
- W4311752815 hasConcept C2779548794 @default.
- W4311752815 hasConcept C2780690907 @default.
- W4311752815 hasConcept C2911091166 @default.
- W4311752815 hasConcept C61511704 @default.
- W4311752815 hasConcept C71924100 @default.
- W4311752815 hasConceptScore W4311752815C120665830 @default.
- W4311752815 hasConceptScore W4311752815C121332964 @default.
- W4311752815 hasConceptScore W4311752815C121608353 @default.
- W4311752815 hasConceptScore W4311752815C126322002 @default.
- W4311752815 hasConceptScore W4311752815C141071460 @default.
- W4311752815 hasConceptScore W4311752815C16005928 @default.
- W4311752815 hasConceptScore W4311752815C2776694085 @default.
- W4311752815 hasConceptScore W4311752815C2777063308 @default.
- W4311752815 hasConceptScore W4311752815C2777408962 @default.
- W4311752815 hasConceptScore W4311752815C2778461978 @default.
- W4311752815 hasConceptScore W4311752815C2778566413 @default.
- W4311752815 hasConceptScore W4311752815C2779548794 @default.
- W4311752815 hasConceptScore W4311752815C2780690907 @default.
- W4311752815 hasConceptScore W4311752815C2911091166 @default.
- W4311752815 hasConceptScore W4311752815C61511704 @default.
- W4311752815 hasConceptScore W4311752815C71924100 @default.
- W4311752815 hasIssue "Supplement_2" @default.
- W4311752815 hasLocation W43117528151 @default.
- W4311752815 hasLocation W43117528152 @default.
- W4311752815 hasOpenAccess W4311752815 @default.
- W4311752815 hasPrimaryLocation W43117528151 @default.
- W4311752815 hasRelatedWork W2040551518 @default.
- W4311752815 hasRelatedWork W2312180805 @default.
- W4311752815 hasRelatedWork W2591026663 @default.
- W4311752815 hasRelatedWork W2751246376 @default.
- W4311752815 hasRelatedWork W2804042555 @default.
- W4311752815 hasRelatedWork W2920115754 @default.
- W4311752815 hasRelatedWork W3000385729 @default.
- W4311752815 hasRelatedWork W3183217309 @default.
- W4311752815 hasRelatedWork W4280573987 @default.
- W4311752815 hasRelatedWork W4365152127 @default.
- W4311752815 hasVolume "9" @default.
- W4311752815 isParatext "false" @default.
- W4311752815 isRetracted "false" @default.
- W4311752815 workType "article" @default.